版本:
中国

BRIEF-Seattle Genetics starts phase 1 trial of SGN-CD123A for patients with relapsed leukemia

Sept 19 Seattle Genetics Inc

* CD123A for patients with relapsed or refractory acute myeloid leukemia Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐